IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

计划入组 680 人 · 首次发布于 2023 年 11 月 1 日

PRISM Trial

计划入组 4,800 人

Fresnel Prism in Low Vision Patients With Homonymous Hemianopia Defect in Cipto Mangunkusumo Hospital

计划入组 25 人 · 首次发布于 2026 年 4 月 15 日

MEL-0614

PDC*mel

Bria-Mel

PRISM PHARMACEUTICALS

Pakistan

PF PRISM C.V.

Netherlands

PRISM Pharma Co., Ltd.

Japan

Immunocore Reports Strong KIMMTRAK Sales Growth and Advances Clinical Pipeline in 2024

Immunocore Advances Clinical Pipeline with Multiple Phase 3 Trials and New Drug Candidates

Immunocore Outlines 2026 Strategic Priorities with Focus on Melanoma Franchise Expansion and Pipeline Advancement